Socioeconomic considerations in erectile dysfunction treatment

Area of Science:

• Urology
• Health Economics
• Pharmacoeconomics

Background:

• Erectile dysfunction (ED) significantly impacts patient quality of life and incurs healthcare costs.
• The advent of oral phosphodiesterase type 5 inhibitors, notably sildenafil, has transformed ED management.
• Previous treatment paradigms for ED were often invasive or less effective, limiting patient access and adherence.

Purpose of the Study:

• To analyze the socioeconomic shifts in erectile dysfunction care following the introduction of oral therapies.
• To provide a descriptive and analytic economic assessment of the implications of ED treatment.
• To understand the evolving patient demographics and treatment-seeking behaviors for ED.

Main Methods:

• Review of healthcare utilization and cost data related to ED treatment.
• Analysis of patient demographic trends before and after the widespread adoption of oral ED medications.
• Economic modeling to assess the cost-effectiveness and societal impact of ED therapies.

Main Results:

• Significant expansion in the patient population seeking ED treatment since the introduction of sildenafil.
• Shift in treatment preferences towards oral pharmacotherapy due to efficacy and convenience.
• Increased healthcare resource utilization associated with a broader ED patient base.

Conclusions:

• Oral ED therapies like sildenafil have dramatically altered the socioeconomic landscape of erectile dysfunction.
• The expanded patient pool presents both opportunities for improved health outcomes and challenges for healthcare resource allocation.
• Further pharmacoeconomic research is warranted to optimize treatment strategies and manage the economic burden of ED.